trending Market Intelligence /marketintelligence/en/news-insights/trending/xux4h5wr76zjxzztqdxnua2 content esgSubNav
In This List

Innate Immunotherapeutics changes name to Amplia Therapeutics

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Innate Immunotherapeutics changes name to Amplia Therapeutics

Innate Immunotherapeutics Ltd. is changing its name to Amplia Therapeutics Ltd.

The Australian pharmaceutical company will also change its stock code to ATX from IIL. Shareholders approved the changes at their annual general meeting in August.

The company said the changes are part of a wider branding refresh, as it focuses on therapeutic targets called focal adhesion kinase inhibitors. These can sensitize certain tumors to cancer drugs and chemotherapies.

Recently, the company found itself at the center of a U.S. congressman's insider trading scandal.